OTC drugs and dietary supplements are regulated under fundamentally different legal frameworks. The gap between them is not a matter of degree — it is a categorical difference in FDA authority, manufacturing requirements, and label language constraints. Understanding this distinction before you engage any manufacturer is the most important foundation for OTC private label sourcing.

The Federal Food, Drug, and Cosmetic Act (FDCA). OTC drugs are regulated as drugs under the FDCA. A product is a drug if it is intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body in a way that requires FDA pre-clearance or monograph conformance. An ibuprofen tablet, an antihistamine tablet, an antacid — these are drugs. Their legal path to market is either (a) conformance to an FDA-established OTC monograph or (b) an approved New Drug Application (NDA). There is no third path.

Why supplement experience does not transfer. Brands that have launched dietary supplements under DSHEA sometimes approach OTC private label with the same framework. That framework does not apply. Supplement cGMP (21 CFR Part 111) is not pharmaceutical cGMP (21 CFR Parts 210/211). A cGMP-certified supplement manufacturer is not qualified to manufacture OTC drugs without separate FDA Drug Establishment Registration and the supporting quality infrastructure. Do not hire a supplement manufacturer to make an OTC drug product — this is an enforcement violation, not a gray area.

The OTC drug market: large, structured, and entry-controlled. The US OTC drug market is approximately $40 billion annually. The major categories — pain relief, cold and allergy, antacids, sleep aids, topicals — are dominated by established national brands but have significant private label activity through retailers (CVS, Walgreens, Walmart, Target all maintain robust private label OTC programs) and through branded DTC operators. Entry is controlled by regulatory requirements, minimum production volumes, and quality system costs that are higher than supplement or food private label. The opportunity is real but the compliance bar is real too.

See also: cGMP explained and FDA registration vs approval.

Drug Establishment Registration is the foundational compliance step for any entity involved in the manufacture, repackaging, relabeling, or salvage of prescription or OTC drugs for US distribution.

Who must register. Any establishment that manufactures, prepares, propagates, compounds, or processes a drug product, or that repackages or relabels it, must register with FDA under 21 CFR Part 207. Foreign establishments whose drug products are imported or offered for import into the US must also register. The registration is establishment-specific — not product-specific. One registration number covers the facility; individual products are listed separately under Drug Listing.

The FEI number. FDA assigns each registered establishment a Facility Establishment Identifier (FEI) — a 7-digit number. This is the Drug Establishment Registration number you request from a prospective manufacturer. Verify it on the FDA Drug Establishment Registration & Listing database (DRLDB), publicly searchable at fda.gov. An FEI that doesn't appear in the database — or appears as inactive — means the facility is not registered to manufacture drugs. Full stop.

Drug Listing requirement. Separate from establishment registration, every commercial drug product must be listed with FDA under 21 CFR Part 207.57. Drug Listing is product-specific: it includes the product's NDC number, active and inactive ingredients, dosage form, route of administration, and labeling. Drug Listing must be updated when the product or its labeling changes. Your contract manufacturer typically handles drug listing for products they manufacture under their label — but if you are the labeled entity, you are responsible for the drug listing. Confirm responsibility in the manufacturing agreement.

Annual registration renewal. Drug Establishment Registration must be renewed annually between October 1 and December 31 each year. Failure to renew results in the establishment being listed as "not registered" — which means products from that facility technically cannot be distributed commercially. Ask your manufacturer when their last renewal was submitted and confirmed. This is a routine compliance step that gets missed at poorly run facilities.

The OTC monograph system is the legal framework that allows most non-prescription drugs to be marketed in the US without a full New Drug Application. Understanding the monograph system is the operational core of OTC private label sourcing.

What a monograph specifies. An OTC monograph is a published FDA regulation (in the Code of Federal Regulations) for a specific therapeutic category. It specifies: permitted active ingredients and their concentration ranges; permitted dosage forms; required and permitted indications and directions for use; required warnings; prohibited claims; inactive ingredient limits where relevant; and required label format (Drug Facts panel). A product that meets all elements of an applicable monograph is considered "generally recognized as safe and effective" (GRASE) and may be marketed without an NDA.

Monograph categories relevant to private label. The major OTC monograph categories include: internal analgesics (aspirin, ibuprofen, acetaminophen, naproxen sodium); antacids (calcium carbonate, magnesium hydroxide, sodium bicarbonate); antihistamines (diphenhydramine, loratadine, cetirizine); nasal decongestants (phenylephrine, oxymetazoline); cough suppressants (dextromethorphan); expectorants (guaifenesin); topical analgesics (lidocaine, menthol); and external analgesics. Each category has its own monograph — confirm which regulation governs your specific product.

The CARES Act OTC monograph reform. The CARES Act of 2020 significantly restructured the OTC monograph system. FDA now has authority to issue and finalize monographs via administrative order rather than the slow rulemaking process. This has streamlined the path for monograph updates but also means the regulatory landscape changes more quickly. Your manufacturer's regulatory team should be monitoring monograph updates that affect your product category. If they're not, that's a gap you need to close.

What happens when you go outside the monograph. Adding an active ingredient not in the monograph, using a dose outside the monograph's permitted range, or making a claim not covered by the monograph — any of these converts your product into an unapproved new drug. An unapproved new drug cannot be legally marketed in the US. FDA enforcement in this space includes warning letters, import alerts, seizure, and injunctions. Private Label Supply does not facilitate sourcing for products that cannot be lawfully marketed — we help clients understand and comply with the applicable regulatory framework, not circumvent it.

See also: FDA registration vs approval and formula development services.

The National Drug Code (NDC) is the unique identifier for every drug product marketed in the US. Every OTC drug label must display an NDC number. Here is how the NDC system works for private label operators.

The three-segment structure. The NDC has three segments: the labeler code, the product code, and the package code. The labeler code is a 4–6 digit number assigned by FDA to the entity that labels (brands) the drug product — this is you, the private label brand owner. The product code is 3–4 digits, assigned by the labeler to distinguish among different products. The package code is 1–2 digits, identifying package size and type. Together they form a 10-digit code (various formatting conventions exist, including the 5-4-2 and 5-3-2 formats). The FDA requires the NDC to be displayed prominently on the label.

Applying for an NDC labeler code. If you are the entity whose name appears on the label, you must apply for an NDC labeler code from FDA through the Drug Establishment Registration and Listing system (eSPL). The application requires establishment registration first — you must be registered as a drug establishment before you can receive a labeler code. Budget 4–8 weeks for the registration and labeler code assignment process. The labeler code is yours permanently — once assigned, it is used on all drug products you label.

Labeler responsibility in private label arrangements. In a private label OTC drug arrangement, there is typically the manufacturer (who holds the FEI registration and manufactures under 21 CFR Parts 210/211) and the labeler (whose brand name appears on the label). These may be the same entity or different entities. If your contract manufacturer is the labeler — their name and NDC labeler code on the label — you have a straightforward arrangement but less brand control. If you want your brand name and NDC on the label, you are the labeler and carry the regulatory responsibilities that come with it. Define this clearly in the manufacturing agreement before any label work begins.

NDC listing maintenance. After your product enters commerce, you must submit drug listing information to FDA twice a year (June and December), or update it within 30 days of any change in labeling or product status. NDC listing is ongoing — it is not a one-time submission. Failure to maintain current drug listing is a regulatory violation that can result in import alerts or enforcement action.

Pharmaceutical cGMP is materially more demanding than dietary supplement cGMP. The requirements under 21 CFR Parts 210 and 211 apply to all finished pharmaceutical dosage form manufacturers, including OTC drug manufacturers. Here are the operational differences that matter for private label sourcing.

Batch record review and product release. Under 21 CFR Part 211, every batch of finished drug product must be reviewed by quality control and formally released before distribution. The batch release process includes review of all production records, all in-process testing results, all finished product testing results, and any deviations or investigations that occurred during manufacturing. A batch cannot ship until quality control signs the release. This is a formal, documented step — not the informal review that may occur at a supplement facility.

Out-of-specification (OOS) investigation requirements. If any test result for a drug batch falls outside specifications — including both in-process and finished-product testing — a formal OOS investigation is required under FDA guidance. The investigation must document the root cause, assess whether the OOS result is attributable to a laboratory error or a manufacturing error, and determine whether the batch can be released or must be rejected. OOS investigations add days to weeks to the production-to-shipment timeline. Supplement manufacturers don't have equivalent mandatory investigation protocols.

Equipment validation and cleaning validation. Pharmaceutical manufacturing equipment must be validated — documented evidence that it performs consistently within established limits. Equipment cleaning validation is required for product changeovers — documented proof that cleaning procedures remove residues of previous products below defined limits. This is particularly rigorous for shared-equipment facilities. A pharmaceutical contract manufacturer should be able to provide cleaning validation documentation for their production lines upon request.

Annual product review (APR). Each year, manufacturers are required to conduct a product-specific review that covers: all batches produced in the year, all OOS investigations, all complaints, all stability data, and the performance of the quality control procedures. The APR is a QC document but also a management review that identifies trends and process improvements. Ask to see the APR protocol as part of your manufacturer evaluation — the existence and quality of this document reflects the facility's quality culture.

The cost of pharmaceutical cGMP compliance. Running a facility under 21 CFR Parts 210/211 costs materially more than running a supplement facility under 21 CFR Part 111. Validation activities, dedicated quality personnel, batch record infrastructure, and the frequency of regulatory inspections all drive higher operating costs. These costs flow through to higher per-unit COGS and higher minimum run volumes — which is why OTC drug private label MOQs are 5–10x the typical supplement MOQ. The economics make sense at scale; they don't make sense for 500-unit test runs.

See also: third-party testing requirements and batch testing glossary.

OTC drug production economics are driven by pharmaceutical manufacturing overhead — validation, QC release, batch record infrastructure — that exists at a relatively fixed cost regardless of run size. This drives minimum volumes and timelines that are significantly higher than supplement or food private label.

Typical MOQ ranges. Solid dose (tablets, capsules, caplets): 5,000–25,000 units is a common commercial minimum. Some facilities have higher minimums — 50,000+ units — due to tablet press tooling minimums and batch record cost amortization. Liquid OTC (cough syrup, antacids, eye drops): 5,000–15,000 units typical, driven by filling line minimum batch sizes. Topical OTC (creams, ointments, gels): 2,000–10,000 units for stock formulas, 10,000+ for custom formulas. Strip-pack or blister-pack packaging adds additional minimums — packaging line setups are expensive and must be amortized over minimum run quantities.

Lead times by product type. Established monograph products with existing validated formulas at a qualified manufacturer: 12–16 weeks from signed PO to finished goods. This covers raw material procurement, manufacturing, QC testing, batch record review, and quality release. New formula development on an established monograph: 18–28 weeks. Add formulation development, analytical method development, stability testing, and validation of the new formula. Novel or complex OTC products outside established monographs: 24–36+ weeks, including the regulatory review step for any NDA pathway work.

The quality release bottleneck. The quality release step — batch record review, final product testing, QC sign-off — is mandatory and cannot be compressed. For a busy pharmaceutical contract manufacturer during peak season (cold and flu season, for example), quality release queues can add 2–4 weeks to the nominal lead time. Build schedule buffer into any OTC drug launch plan for quality release delays. Unlike supplement contract manufacturing, you cannot push a batch out the door before QC has released it — the regulatory risk is unacceptable.

Packaging lead times in OTC drug. OTC drug packaging is more complex than supplement packaging: Drug Facts panel requirements, NDC barcode placement, child-resistant packaging compliance (PPPA requirements for many OTC categories), tamper-evident packaging requirements. Custom-printed blister packs, cartons with specific regulatory copy, and child-resistant bottle caps all have tooling and print lead times. Budget packaging procurement in parallel with manufacturing setup — packaging is frequently the critical path in OTC private label first runs.

See also: lead time glossary and lead time estimator tool.